Back to Top


A how-to on positioning yet another EGFR TKI (#6) for success

With already five EGFR TKIs to choose from, is there room for one more? Janssen thinks there is, betting on a combination strategy to defeat osimertinib

Osimertinib granted FDA BTD for adjuvant treatment of resectable, EGFRmut NSCLC

Interim analysis of the phase 3 ADAURA study showed a significant improvement in DFS, and study was unblinded early in April 2020 (AZ press release)

Subscribe to RSS - EGFR